Online citations, reference lists, and bibliographies.
← Back to Search

Immunohistochemical Detection Of GLUT-1 Can Discriminate Between Reactive Mesothelium And Malignant Mesothelioma

Y. Kato, K. Tsuta, K. Seki, A. Maeshima, Shun-ichi Watanabe, K. Suzuki, H. Asamura, R. Tsuchiya, Y. Matsuno
Published 2007 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The separation of benign reactive mesothelium (RM) from malignant mesothelial proliferation can be a major challenge. A number of markers have been proposed, including epithelial membrane antigen, p53 protein, and P-glycoprotein. To date, however, no immunohistochemical marker that allows unequivocal discrimination of RM from malignant pleural mesothelioma (MPM) has been available. A family of glucose transporter isoforms (GLUT), of which GLUT-1 is a member, facilitate the entry of glucose into cells. GLUT-1 is largely undetectable by immunohistochemistry in normal epithelial tissues and benign tumors, but is expressed in a variety of malignancies. Thus, the expression of GLUT-1 appears to be a potential marker of malignant transformation. Recently, in fact, some studies have shown that GLUT-1 expression is useful for distinguishing benign from malignant lesions. The purpose of the present study was to evaluate the diagnostic utility of GLUT-1 expression for diagnostic differentiation between RM and MPM. Immunohistochemical staining for GLUT-1 was performed in 40 cases of RM, 48 cases of MPM, and 58 cases of lung carcinoma. Immunohistochemical GLUT-1 expression was seen in 40 of 40 (100%) MPMs, and in all cases the expression was demonstrated by linear plasma membrane staining, sometimes with cytoplasmic staining in addition. GLUT-1 expression was also observed in 56 out of 58 (96.5%) lung carcinomas. On the other hand, no RM cases were positive for GLUT-1. GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of RM from MPM, whereas it cannot discriminate MPM from lung carcinoma.
This paper references
10.1309/XL6K-8E62-9FLD-V8Q8
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
10.1002/PATH.1711680407
p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin‐fixed paraffin sections
F. Mayall (1992)
Utility of epithelial membrane antigen and p53 in the differential diagnosis of benign reactive processes from malignancy in pleural biopsy specimens
A Salas (1999)
10.1016/0898-6568(93)90028-K
Growth factors, mitogens, oncogenes and the regulation of glucose transport.
N. W. Merrall (1993)
10.1016/0046-8177(94)90115-5
p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
P. Cagle (1994)
10.1159/000326249
Diagnostic Utility of GLUT-1 Expression in the Cytologic Evaluation of Serous Fluids
A. Afify (2005)
10.1016/0065-2571(91)90015-E
Application of metabolic-control logic to fuel utilization and its significance in tumor cells.
E. Newsholme (1991)
10.1097/00000478-198912000-00004
Immunoproliferative small-intestinal disease. An immunohistochemical study.
P. Isaacson (1989)
10.1002/jcp.20606
Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues
A. Godoy (2006)
p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
V. Esposito (1997)
10.1002/PATH.1711670102
Immunoreactivity for the β chain of the platelet‐derived growth factor receptor in malignant mesothelioma and non‐neoplastic mesothelium
M. Ramael (1992)
10.1146/ANNUREV.NU.16.070196.001315
Structure, function, and regulation of the mammalian facilitative glucose transporter gene family.
A. L. Olson (1996)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1002/PATH.1711670103
Immunoreactivity for p‐170 glycoprotein in malignant mesothelioma and in non‐neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB‐1
M. Ramael (1992)
10.1111/j.1365-2559.1992.tb00403.x
p53 expression is common in malignant mesothelioma
G. Kafiri (1992)
10.1016/S0022-5347(01)67725-5
Investigative Urology: Immunohistochemical Localization of Glucose Transporters in Human Renal Cell Carcinoma
Yasushi Nagase (1995)
10.1111/J.1432-1033.1994.TB18550.X
Facilitative glucose transporters.
M. Mueckler (1994)
10.1002/IJC.2910560503
Expression of glucose transporters in head‐and‐neck tumors
P. Mellanen (1994)
Correspondence re: Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H: Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998; 11:437-443.
S. Zador (1998)
Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage.
T. Ito (1998)
10.1016/S0090-4295(99)00474-4
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder.
S. Chang (2000)
10.1007/BF00195777
Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium
K. Segers (1994)
GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions.
D. Burstein (1998)
10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7
Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival
M. Younes (1997)
10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X
Overexpression of glut‐1 glucose transporter in human breast cancer an immunohistochemical study
R. Brown (1993)
10.1002/PATH.1711680406
Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium
M. Ramael (1992)
10.1038/modpathol.3880384
Glucose Transporter Glut-1 Is of Limited Value for Detecting Breast Carcinoma in Serous Effusions
R. Zimmerman (2001)
Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers.
M. Younes (1996)
10.1043/1543-2165(2005)129[1407:IDOEMA]2.0.CO;2
Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
N. Ordóñez (2005)
10.1002/DC.20127
Diagnostic value of GLUT‐1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine‐needle aspiration biopsy material
Michael F Weiner (2004)
Immunohistochemical localization of glucose transporters in human renal cell carcinoma.
Y. Nagase (1995)
10.1593/NEO.04577
[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.
M. Mamede (2005)
10.1097/00000478-200008000-00024
Primary giant cell tumors of soft tissue.
Allen Pw (2000)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
10.1097/00000478-200009000-00001
The separation of benign and malignant mesothelial proliferations.
A. Churg (2000)
10.1046/j.1365-2559.1997.5460776.x
Pathology of malignant mesothelioma
R. Attanoos (1997)
Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.
A. Clavo (1995)
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.
R. Brown (1999)
10.1002/cncr.21714
The utility of GLUT‐1 immunolocalization in cell blocks
V. Chandan (2006)
10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F
The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis
P. Cury (1999)



This paper is referenced by
10.21037/SHC.2019.01.04
Diagnostic performance of glucose transporter-1 immunohistochemistry in malignant pleural mesothelioma: a meta-analysis
M. Barone (2019)
10.1016/B978-1-4160-5766-6.00016-9
Chapter 12 – Immunohistology of Lung and Pleural Neoplasms
S. Hammar (2011)
10.1007/978-3-030-36438-0_21
Non-infectious Benign Diseases of the Pleura
A. Weissferdt (2020)
10.1007/S12156-007-0011-7
Advances in diagnosis and treatment of malignant pleural mesothelioma
G. Scagliotti (2007)
10.1136/jcp.2010.076794
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
C. Chung (2010)
10.1007/978-1-4614-1776-7_3
Reactive Mesothelial Hyperplasia
S. Ali (2012)
10.1080/15321819.2012.690356
IS GALECTIN-3 ANTIBODY A USEFUL MARKER IN THE DIAGNOSIS OF MALIGNANT PLEURAL MESOTHELIOMA?
Mona Mlika (2013)
β-catenin expression in benign and malignant pleural disorders.
W. Anani (2011)
10.5858/arpa.2010-0216-RA
Epithelioid lesions of the serosa.
S. Anttila (2012)
Immunohistochemical Detection of Glut-1 Helps to Distinguish between Reactive Mesothelium and Malignant Mesothelioma
Jing Fung Kee (2010)
10.1159/000339259
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
10.1097/DAD.0b013e3182858460
Multilocular Mesothelial Proliferation Involving the Skin of the Umbilicus
A. M. Konstantinova (2013)
10.1002/dc.22821
CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma
C. Pinheiro (2012)
10.1186/1756-9966-27-34
Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions
P. Parente (2008)
10.5146/tjpath.2018.01435
Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma.
Ceren Boyacı (2019)
Linfoma anaplásico de células grandes. Primario de hueso
Gabriel Juan Mandujano-Álvarez (2009)
10.1309/AJCPWFW7O1FVFLKT
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
10.1165/rcmb.2009-0340OC
Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism.
E. Ranzato (2011)
Down regulation of miR-148 a is related to enhanced pancreatic cancer pathogenesis through targeting GLUT 1
Linshi Wu (2018)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
mmunohistochemical Features of Malignant Vascular Tumors with Special emphasis on GlUT1, and FkBP12 expressions Malign Vasküler Tümörlerin Morfolojik ve İmmünohistokimyasal Özellikleri ile GLUT1 ve FKBP12 Ekspresyonlarinin Vurgulanmasi
Gökhan GeDİk (2011)
10.5146/tjpath.2013.01158
Value of Glut-1 and Koc Markers in the Differential Diagnosis of Reactive Mesothelial Hyperplasia, Malignant Mesothelioma and Pulmonary Adenocarcinoma / Reaktif Mezotel Hiperplazisi, Malign Mezotelyoma ve Akciğer Adenokarsinomu Ayırıcı Tanısında Glut-1 ve Koc’un Yeri
Özlem Üçer (2013)
10.14670/HH-28.663
Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
T. Horiuchi (2013)
10.5858/arpa.2014-0092-RA
Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update.
K. Zhang (2014)
10.3892/mco.2020.2131
Malignant mesothelioma metastatic to the oral region and latest topics (Review).
Y. Ohnishi (2020)
10.1007/978-981-10-7053-2_15
Malignant Peritoneal Mesothelioma
E. Poli (2018)
10.1016/B978-141604208-2.10035-1
CHAPTER 35 – Immunocytochemistry
M. Chivukula (2008)
10.1097/PAS.0000000000000394
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
10.1136/bcr-2013-009850
Unusual presentation and location pleural malignant mesothelioma
A. Kumar (2013)
10.1097/MPA.0b013e318201c935
GLUT-1 Expression in Pancreatic Neoplasia: Implications in Pathogenesis, Diagnosis, and Prognosis
O. Basturk (2011)
10.1309/DV1JYBL8LLYYT4J5
Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings.
Nilesh P. Patel (2007)
10.1002/dc.21398
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar